Novartis Pharma’s Lutz Hegemann: India Is A Very Prosperous Generic Industry

Neglected Tropical Diseases: Lutz Hegemann EXCLUSIVE | Business 360 | CNBC-TV18Подробнее

BUSINESS BULLETIN - India denies Novartis patent protection on cancer drugПодробнее

Lutz Hegemann, Group Head of Corporate Affairs and Global Health, NovartisПодробнее

Staying ahead of antimicrobial resistanceПодробнее

Novartis verdict fallout: Patents vs patients?Подробнее

Supreme Court backs generics in Novartis drug patent rulingПодробнее

Swiss Pharma MNC Novartis Slams India's Drug Pricing RegimeПодробнее

Novartis ruling shows India doesn't want innovation: Peter PittsПодробнее

[YS TV] Hans-Peter Frank, Novartis, @ Health 2.0 IndiaПодробнее

Novartis and GSK swap assets in pharma industry reshape - economyПодробнее

Still Don't See Basic Drug Discovery Capabilities In India: NovartisПодробнее

Novartis verdict: A lifesaver of poor cancer patients in India?Подробнее

India's Minister for Commerce and Industry on Novartis Patent RulingПодробнее

India Rejects Novartis Cancer-Drug PatentПодробнее

India, the pharmacy of the world -HD-Подробнее

[Industry Voice #15] Pharma Entering New Markets | Sanofi, Novartis, Pfizer CasesПодробнее

Lenias Hwenda I Beyond making medicines, the role of Pharma | Lutz Hegemann President Novartis GH&SПодробнее

India: Novartis Tries to Weaken Patent Laws That Protect PatientsПодробнее

Novartis' plea to patent Glivec in India quashedПодробнее